Clinical Trials Logo

Clinical Trial Summary

Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America and Europe for several clinical use in complicated intraabdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections and community-acquired pneumonia. In common with other beta-lactams, ertapenem exhibits primarily time-dependent activity, and the percentage of the exposure time during which the free drug concentration remain above the MIC (%T>MIC) is the pharmacokinetic/pharmacodynamics (PK/PD) index that best correlates with efficacy. Pathophysiological changes in critically ill patients with severe infections resulting in altered PK patterns that may affect therapeutic plasma concentrations and achievement of PD have been found with several antimicrobial agents. The aim of the study was to determine the PK of ertapenem in patients with urosepsis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Patients With Urosepis and Received Ertapenem for Treatment

NCT number NCT03859362
Study type Interventional
Source Prince of Songkla University
Contact
Status Active, not recruiting
Phase Phase 4
Start date January 2017
Completion date December 31, 2021